Table 1.
Demographics, immunological, and primary antibody defect (PAD)-related characteristics in common variable immunodeficiency (CVID) participants.
| Group 1 Immunized n = 38 | Group 2 Convalescents n = 34 | Group 3 Convalescent/Immunized n = 20 | Groups 1 vs. 2 p-Value | Groups 1 vs. 3 p-Value | Groups 2 vs. 3 p-Value | |
|---|---|---|---|---|---|---|
| Sex, n (%) | 25 (66) | 16 (47) | 12 (60) | 0.157 | 0.776 | 0.408 |
| Age, years, median (IQR) | 54.5 (42.5–60.0) | 49.5 (44.7–59.2) | 49.5 (44.2–62.7) | 0.840 | 0.973 | 0.943 |
| PAD-related complication | ||||||
| Autoimmunity, n (%) | 18 (47) | 9 (26) | 7 (35) | 0.094 | 0.414 | 0.550 |
| Chronic lung disease, n (%) | 8 (21) | 20 (58) | 10 (50) | 0.001 | 0.036 | 0.560 |
| Cancer, n (%) | 2 (5) | 2 (6) | 2 (10) | 1.000 | 0.602 | 0.622 |
| Immunosuppressive treatment, n (%) | 10 (26) | 3 (9) | 2 (10) | 0.069 | 0.186 | 1.000 |
| IgG, g/L, median (IQR) | 6.9 (5.8–8.1) | 7.5 (6.5–8.8) | 7.6 (7.2–8.8) | 0.069 | 0.122 | 0.881 |
| IgA, mg/dL, median (IQR) | 7.0 (0–25.0) | 6.0 (0–28.0) | 4.5 (0–12.8) | 0.541 | 0.599 | 0.401 |
| IgM, mg/dL, median (IQR) | 19.6 (4–42) | 20.0 (5–25.1) | 9.5 (4–25) | 0.576 | 0.355 | 0.648 |
| CD3+, cell/mm3, median (IQR) | 924 (748–1512) | 974 (675–1548) | 879 (639–1412) | 0.513 | 0.255 | 0.335 |
| CD4+, cell/mm3, median (IQR) | 452 (356–811) | 511 (356–811) | 479 (335–838) | 0.756 | 0.801 | 0.992 |
| CD8+, cell/mm3, median (IQR) | 421 (186–692) | 369 (269–710) | 297 (242–521) | 0.741 | 0.281 | 0.095 |
| CD19+, cell/mm3, median (IQR) | 87 (20–184) | 91 (29–172) | 55 (30–131) | 0.564 | 0.150 | 0.272 |
| CD19+CD27+ IgM–IgD–, %, median (IQR) | 3.5 (1–7.7) | 2.0 (0–5.0) | 2.5 (0–5.5) | 0.649 | 0.921 | 0.771 |
| CD19+CD27+IgM–IgD–, cell/mm3, median (IQR) | 1 (0–5.8) | 1.6 (0–4.1) | 2.3 (0.1–4.6) | 0.480 | 0.474 | 0.739 |
| Atypical MBC (ATM) CD19+CD24-CD27–CD38–CD21–, % of CD19+, median (IQR) | 3.69 (2.8–8.1) | 3.4 (2.3–5.2) | 3.1 (2.9–4.1) | 0.469 | 0.613 | 0.863 |